With nearly 20 years of experience, a broad test portfolio, and an innovative perspective, we provide tailored diagnostic and treatment solutions for every patient.
Our tests, designed to address individualized needs, provide guidance in the development of personalized treatment protocols.
Providing reliable and guiding clinical support through pioneering approaches in high-quality precision diagnostic solutions, utilizing CE-IVD marked kits and referenced international bioinformatics analysis systems.
● Our tests are subject to CAP and GENQA External Quality Control.
● We hold ISO:15189 accreditation in accordance with Medical Laboratory Standards.
Our laboratory’s genetic analyses enhance the diagnostic process by providing dependable and guiding clinical insights backed by a team of specialists.
For all solid tumors, we evaluate the tumor's genetic profile using molecular and cytogenetic methods (NGS, dPCR, RT-PCR, and FISH) to support targeted and personalized treatment.
As Nesiller Genetic, we contribute to both carrier screening and infertility assessment processes by identifying hereditary genetic risks in couples planning to conceive, through our carrier and reproductive genetics panels.
We enable the selection of healthy embryos through pre-transfer embryo screening during the IVF process and minimize genetic risks using innovative PGT methods that meet international standards.
We provide personalized diagnostic and treatment solutions for clinically complex cases with overlapping phenotypes, diagnostic challenges, familial risk assessments, and rare complex diseases through WGS, WES, CNV analysis, and mitochondrial DNA (mtDNA) analysis.
Kanda dolaşan tümör DNA’sını (ctDNA) görüntüleme cihazlarından aylar önce tespit eden, FDA onaylı ve kişiye özel moleküler temelli bir kanser takip testidir.
Developed for individuals with a family history of cancer, those seeking to understand their cancer risk, or patients aiming to define treatment options following diagnosis.
FoundationOne Heme is a comprehensive genomic profiling (CGP) test that combines DNA and RNA sequencing for patients with hematologic malignancies and solid tumors.
Pharmacogenetic testing enhances drug effectiveness and supports treatment by personalizing dosage requirements and minimizing potential adverse effects.
Minimal Residual Disease (MRD) testing can detect cancer recurrence months earlier than conventional imaging technologies by analyzing circulating tumor DNA (ctDNA). It is an FDA-approved, personalized molecular assay for cancer monitoring.
Non-Invasive Prenatal Testing (NIPT) is a screening test that analyzes cell-free fetal DNA (cffDNA) in maternal blood from the 10th week of pregnancy onward.
Identifies genetic risk factors associated with Alzheimer’s disease, Parkinson’s disease, and dementia. This panel enables early detection and guides personalized treatment and planning.
Founder & General Manager
“Genetic testing helps my colleagues understand their patients more accurately, monitor them with a personalized and holistic approach, and tailor treatment decisions more effectively.”
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, 34394 Şişli / Istanbul, Turkey
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00
